| Symbol | ARMP |
|---|---|
| Name | ARMATA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 4503 GLENCOE AVENUE, MARINA DEL REY, California, 90292, United States |
| Telephone | +1 858 829-0829 |
| Fax | — |
| — | |
| Website | https://www.armatapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000921114 |
| Description | Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing. Additional info from NASDAQ: |
(90% Positive) ARMATA PHARMACEUTICALS, INC. (ARMP) Announces Clinical Development Update
Read more(99% Neutral) ARMATA PHARMACEUTICALS, INC. (ARMP) Announces New Board Appointment
Read moreNew Form 8-K/A - Armata Pharmaceuticals, Inc. <b>Filed:</b> 2026-06-24 <b>AccNo:</b> 0001104659-26-077313 <b>Size:</b> 188 KB <br />Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read more(90% Positive) ARMATA PHARMACEUTICALS, INC. (ARMP) Announces Clinical Development Update
Read more(99% Neutral) ARMATA PHARMACEUTICALS, INC. (ARMP) Announces Regulatory Update
Read more(70% Positive) ARMATA PHARMACEUTICALS, INC. (ARMP) Reports Q2 2026 Financial Results
Read moreNew Form SCHEDULE 13D/A - Armata Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-13 <b>AccNo:</b> 0001104659-26-060384 <b>Size:</b> 14 KB
Read more(90% Positive) ARMATA PHARMACEUTICALS, INC. (ARMP) Provides Update on need for AP-SA02 Enables more frequent FDA engagement
Read moreDirector Gilmer Daniel B. 🟢 acquired 51.3K shares (1 derivative) of Armata Pharmaceuticals, Inc. (ARMP) at $12.92 Transaction Date: Apr 24, 2026 | Filing ID: 050391
Read moreNew Form 3 - Armata Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050386 <b>Size:</b> 3 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT03395769 | Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphyl… | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03395743 | Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudom… | — | — | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT05616221 | Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 i… | Phase2 | Non-cystic Fibrosis Bronchiectasis | Completed | 2023-01-10 | 2024-08-08 | ClinicalTrials.gov |
| NCT05184764 | Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in S… | Phase1 | Bacteremia | Completed | 2022-04-26 | 2025-01-14 | ClinicalTrials.gov |
| NCT04596319 | Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects … | Phase1 | Cystic Fibrosis | Completed | 2020-12-22 | 2022-12-14 | ClinicalTrials.gov |
| NCT03196219 | A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 … | Phase2 | Dental Caries | Completed | 2017-07-07 | 2018-01-10 | ClinicalTrials.gov |
| NCT03052842 | A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental S… | Phase2 | Dental Caries | Completed | 2017-02-09 | 2017-04-05 | ClinicalTrials.gov |
| NCT03004365 | A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered i… | Phase2 | Dental Caries | Completed | 2017-01-27 | 2017-03-29 | ClinicalTrials.gov |
| NCT02757755 | Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact … | Phase1 | Healthy Volunteers | Completed | 2016-05-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02594254 | Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to … | Phase2 | Dental Caries | Completed | 2015-11-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02509845 | Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult … | Phase2 | Dental Caries | Completed | 2015-07-01 | 2016-03-01 | ClinicalTrials.gov |
| NCT02254993 | Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple… | Phase2 | Dental Caries | Completed | 2014-10-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02044081 | Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth R… | Phase2 | Dental Caries | Completed | 2014-02-01 | 2014-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| C16G2 | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02254993 |
| C16G2 Gel | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02044081 |
| Placebo | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02044081 |
| C16G2 Rinse | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02044081 |
| Placebo (for Cohort 10^9) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| Placebo (for Cohort 10^8) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 (10^9 PFU per phage) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 (10^8 PFU per phage) | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 | Other | Preclinical | — | NO_LONGER_AVAILABLE | NCT03395769 |
| AB-PA01 | Other | Preclinical | — | NO_LONGER_AVAILABLE | NCT03395743 |
| Placebo | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02594254 |
| C16G2 Gel | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02594254 |
| Placebo | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02509845 |
| C16G2 | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT02509845 |
| Placebo | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT03196219 |
| C16G2 | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT03196219 |
| Placebo Strip | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT03052842 |
| C16G2 Strip | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT03052842 |
| Placebo Varnish | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT03004365 |
| C16G2 Varnish | Other | Phase PHASE2 | Dental Caries | COMPLETED | NCT03004365 |
| Placebo | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT04596319 |
| AP-PA02 | Other | Phase PHASE1 | Cystic Fibrosis | COMPLETED | NCT04596319 |
| Placebo | Other | Phase PHASE2 | Non-cystic Fibrosis Bronchiectasis | COMPLETED | NCT05616221 |
| AP-PA02 | Other | Phase PHASE2 | Non-cystic Fibrosis Bronchiectasis | COMPLETED | NCT05616221 |
| Placebo | Other | Phase PHASE1 | Bacteremia | COMPLETED | NCT05184764 |
| AP-SA02 | Other | Phase PHASE1 | Bacteremia | COMPLETED | NCT05184764 |
| AP-SA02 | BIOLOGICAL | Phase PHASE1 | Bacteremia | COMPLETED | NCT05184764 |
| AP-PA02 | BIOLOGICAL | Phase PHASE2 | Non-cystic Fibrosis Bronchiectasis | COMPLETED | NCT05616221 |
| AB-SA01 | BIOLOGICAL | Preclinical | — | NO_LONGER_AVAILABLE | NCT03395769 |
| AB-PA01 | BIOLOGICAL | Preclinical | — | NO_LONGER_AVAILABLE | NCT03395743 |
| Placebo Strip | OTHER | Phase PHASE2 | Dental Caries | COMPLETED | NCT03052842 |
| C16G2 Strip | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03052842 |
| Placebo Varnish | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03004365 |
| C16G2 Varnish | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03004365 |
| Placebo (for Cohort 10^9) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| Placebo (for Cohort 10^8) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 (10^9 PFU per phage) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| AB-SA01 (10^8 PFU per phage) | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02757755 |
| C16G2 | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT03196219 |
| C16G2 Gel | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT02594254 |
| Placebo | OTHER | Phase PHASE2 | Non-cystic Fibrosis Bronchiectasis | COMPLETED | NCT05616221 |
| C16G2 Rinse | DRUG | Phase PHASE2 | Dental Caries | COMPLETED | NCT02044081 |